| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Broadcom Q4 Earnings Beat Estimates, Revenues Rise Y/Y, Shares Fall | ||
| Fr | SkyWest's EPS Estimates Northbound: Should Investors Buy the Stock? | ||
| Fr | APPS vs. PUBM: Which Stock Has an Edge in the AdTech Market? | ||
| Fr | Should Investors Hold Old Dominion Stock Despite Its Higher Valuation? | ||
| Fr | NVO Down 42% Year to Date: Is This an Indication to Sell the Stock? | ||
| Fr | Can Opdivo's Label Expansions Help Bristol Myers Sustain Its Momentum? | ||
| Fr | Can Tesla's New Discounts on Model Y Help Boost Q4 Deliveries? | ||
| Fr | Synopsys Q4 Earnings Surpass Estimates, Revenues Rise Y/Y | ||
| Fr | Daktronics' Q2 Earnings Beat Estimates, Revenues Rise Y/Y, Shares Fall | ||
| Fr | ATRC Treats First Patients Using Novel Dual-Energy PFA-RFA Platform | ||
| Fr | Can Verizon's Empower Field Network Infrastructure Upgrade Aid Shares? | ||
| Fr | Clorox's Brand Investments Are Up: Will They Translate to Growth? | ||
| Fr | DraftKings' iGaming Up 25%: A Second Growth Engine Emerging? | ||
| Fr | Is Comfort Systems Positioned for Long-Term Pharma Project Demand? | ||
| Fr | Can Flex Offset Automotive Headwinds in Its Reliability Segment? | ||
| Fr | Can PLAY's Revamped Remodel Blueprint Catalyze Its Next Growth Cycle? | ||
| Fr | Suncor Unveils 2026 Guidance Focused on Growth & Superior Returns | ||
| Fr | GSK Gets FDA Nod for Blujepa in Uncomplicated Urogenital Gonorrhea | ||
| Fr | Will the CEC Acquisition Strengthen Sterling's Margin Profile in 2026? | ||
| Fr | Can MRK's New Drugs & Pipeline Help Navigate the Looming Keytruda LOE? | ||
| Fr | CBLL Gets FDA Consent for One-of-a-Kind Delirium Monitoring Solution | ||
| Fr | Fed Cuts Rate: Will This Accelerate Morgan Stanley's IB Fee Growth? | ||
| Fr | Can DUK's Massive Clean Energy Investments Drive Long-Term Growth? | ||
| Fr | TJX Stock Up 30% in 2025: What's the Smart Move for 2026? | ||
| Fr | After a 42% Six-Month Rally, What's Next for Apple Stock in 2026? |